Dr. Abato is a medicinal chemist and pharmaceutical technology expert with more than 20 years of experience, specializing in drug research, drug formulation, development, efficacy, dosing routes, pharmacokinetics and pre-clinical testing. As principal scientist and project coordinator at Paratek Pharmaceuticals, he was involved in the discovery and development of novel human therapeutics, including the new antibiotic Omadacycline currently in Phase III clinical development. In addition, Dr. Abato contributed significantly to the discovery of five preclinical candidates for multiple sclerosis, arthritis and spinal muscular atrophy. He has been involved in all aspects of drug research and development, including synthesis and purification, efficacy and pharmacokinetics testing in-­vitro and in-­vivo and the management of contract research organizations (CRO) to support pre-­clinical testing. He co-­authored a pre­investigational new drug (IND) proposal that had a favorable review by the FDA in 2013. As a consultant, Dr. Abato regularly advises clients about issues relating to Hatch-Waxman Act abbreviated new drug application (ANDA) matters.


  • Holds Multiple Patents
    • 7-­Disubstituted-­Ph Tetracycline Compounds for the Treatment of SMA
    • Tetracycline Compounds for the Treatment of Rheumatoid Arthritis and Related Methods of Treatment
    • Substituted Tetracycline Compounds for Treatment of Bacterial Infections and Neoplasms
    • Preparation of 10-­Substituted Tetracycline Compounds as Antibiotics
    • Preparation of Substituted Tetracycline Compounds for the Treatment of Bacterial Infections and Neoplasms
    • Preparation of Substituted Tetracycline Analogs for Use in Antibiotic Pharmaceutical Compositions
  • PhD, Chemistry, Brown University, 2002
  • BA, Chemistry, Minor in Biology, Rhode Island College, 1996


  • Excellence in Organic Chemistry, American Polymer Society

* Partial bio; contact Humatec for comprehensive CV